Amphastar Pharmaceuticals, Inc. (AMPH) Stock Score, Valuation & Financial Research
Amphastar Pharmaceuticals, Inc. is in the Healthcare sector and Drug Manufacturers - Specialty & Generic industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 62/100.
Quick answer for AMPH
Amphastar Pharmaceuticals, Inc. currently has a Wall Street Score of 62/100. The stored market price is $23.78. Its financial score is 25/100. Its valuation score is 97/100. The latest WSS change is +1.0 points. These figures are a research snapshot, not a buy or sell recommendation.
What Amphastar Pharmaceuticals, Inc. does
Amphastar Pharmaceuticals, Inc., established in 1996 and based in Rancho Cucamonga, California, functions as a biopharmaceutical enterprise. The company is engaged in the creation, production, commercialization, and distribution of both generic and proprietary pharmaceutical products, which include injectables, inhalants, and intranasal formulations. Its market presence extends across the United States, China, and France. Amphastar's operations are divided into two primary segments: Finished Pharmaceutical Products and Active Pharmaceutical Ingredients (API). The company's extensive product portfolio encompasses a variety of crucial medications. These feature Primatene Mist, an over-the-counter epinephrine inhaler for the temporary alleviation of mild asthma symptoms; Enoxaparin, a low molecular weight heparin utilized for the prevention and treatment of deep vein thrombosis; and Naloxon
AMPH financial snapshot
- Wall Street Score:
- 62/100
- Current price:
- $23.78
- Market capitalization:
- $1.05B
- Revenue:
- $730.0M
- Net income:
- $78.5M
- Free cash flow:
- $121.2M
- Cash:
- $223.6M
- Total debt:
- $688.3M
- EPS:
- 1.74
- P/E ratio:
- 13.7x
- Financial score:
- 25/100
- Valuation score:
- 97/100
- Revenue score:
- 25/100
What stands out
- Reported year-over-year revenue growth is +0.0%.
- Free cash flow is $121.2M, showing positive cash generation.
- The balance sheet shows $223.6M of cash versus $688.3M of total debt, so leverage deserves attention.
- The latest Wall Street Score change is +1.0 points: AMPH increased 1 points because Valuation improved by 14.6 points.
What the numbers mean
Its current valuation score is 97/100, which Wall Street Score classifies as strong within the model's valuation framework.
The financial score is 25/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-09-08.
How to research AMPH
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.